Related references
Note: Only part of the references are listed.Haematopoietic stem and progenitor cells from human pluripotent stem cells
Ryohichi Sugimura et al.
NATURE (2017)
Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study
Parinda A. Mehta et al.
BLOOD (2017)
Late effects in patients with Fanconi anemia following allogeneic hematopoietic stem cell transplantation from alternative donors
P. Anur et al.
BONE MARROW TRANSPLANTATION (2016)
Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic
Aniello Cerrato et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
The Fanconi anaemia pathway: newyplayers and new functions
Raphael Ceccaldi et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2016)
Unreplicated DNA remaining from unperturbed S phases passes through mitosis for resolution in daughter cells
Alberto Moreno et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
CRISPR/Cas9 Targeted Gene Editing and Cellular Engineering in Fanconi Anemia
Mark J. Osborn et al.
STEM CELLS AND DEVELOPMENT (2016)
Improved Genome Editing Efficiency and Flexibility Using Modified Oligonucleotides with TALEN and CRISPR-Cas9 Nucleases
Jean-Baptiste Renaud et al.
CELL REPORTS (2016)
Lessons Learned from Two Decades of Clinical Trial Experience in Gene Therapy for Fanconi Anemia
Jennifer E. Adair et al.
CURRENT GENE THERAPY (2016)
Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR
Maximilian Haeussler et al.
GENOME BIOLOGY (2016)
Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors
Christopher J. Lord et al.
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
Alternative donor hematopoietic cell transplantation for Fanconi anemia
Margaret L. MacMillan et al.
BLOOD (2015)
Fanconi Anemia Gene Editing by the CRISPR/Cas9 System
Mark J. Osborn et al.
HUMAN GENE THERAPY (2015)
Engineered CRISPR-Cas9 nucleases with altered PAM specificities
Benjamin P. Kleinstiver et al.
NATURE (2015)
Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition
Benjamin P. Kleinstiver et al.
NATURE BIOTECHNOLOGY (2015)
7Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors
Maria Teresa Esposito et al.
NATURE MEDICINE (2015)
Regulation of Gene Editing Activity Directed by Single-Stranded Oligonucleotides and CRISPR/Cas9 Systems
Pawel Bialk et al.
PLOS ONE (2015)
Stress and DNA repair biology of the Fanconi anemia pathway
Simonne Longerich et al.
BLOOD (2014)
Targeted gene therapy and cell reprogramming in Fanconi anemia
Paula Rio et al.
EMBO MOLECULAR MEDICINE (2014)
TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity
Claudio Mussolino et al.
NUCLEIC ACIDS RESEARCH (2014)
Homology-directed repair of DNA nicks via pathways distinct from canonical double-strand break repair
Luther Davis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Fanconi anaemia and the repair of Watson and Crick DNA crosslinks
Molly C. Kottemann et al.
NATURE (2013)
DNA targeting specificity of RNA-guided Cas9 nucleases
Patrick D. Hsu et al.
NATURE BIOTECHNOLOGY (2013)
RNA-Guided Human Genome Engineering via Cas9
Prashant Mali et al.
SCIENCE (2013)
Multiplex Genome Engineering Using CRISPR/Cas Systems
Le Cong et al.
SCIENCE (2013)
Overcoming reprogramming resistance of Fanconi anemia cells
Lars U. W. Mueller et al.
BLOOD (2012)
The clinical phenotype of children with Fanconi anemia caused by biallelic FANCD1/BRCA2 mutations
Kasiani Myers et al.
PEDIATRIC BLOOD & CANCER (2012)
The role of PARP in DNA repair and its therapeutic exploitation
M. Javle et al.
BRITISH JOURNAL OF CANCER (2011)
Tracking genome engineering outcome at individual DNA breakpoints
Michael T. Certo et al.
NATURE METHODS (2011)
Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting
Tomas Cermak et al.
NUCLEIC ACIDS RESEARCH (2011)
Chromosomal Integration of Adenoviral Vector DNA In Vivo
Sam Laurel Stephen et al.
JOURNAL OF VIROLOGY (2010)
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Marina Cavazzana-Calvo et al.
NATURE (2010)
The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy
Eugenio Montini et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Comprehensive genomic access to vector integration in clinical gene therapy
Richard Gabriel et al.
NATURE MEDICINE (2009)
Enzymatic assembly of DNA molecules up to several hundred kilobases
Daniel G. Gibson et al.
NATURE METHODS (2009)
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Salima Hacein-Bey-Abina et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Hot spots of retroviral integration in human CD34+ hematopoietic cells
Claudia Cattoglio et al.
BLOOD (2007)
Gene targeting using zinc finger nucleases
MH Porteus et al.
NATURE BIOTECHNOLOGY (2005)
Highly efficient endogenous human gene correction using designed zinc-finger nucleases
FD Urnov et al.
NATURE (2005)
High-resolution genome-wide mapping of transposon integration in mammals
SR Yant et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Detection of somatic mosaicism and classification of Fanconi anemia patients by analysis of the FA/BRCA pathway
J Soulier et al.
BLOOD (2005)
Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood
B Hirsch et al.
BLOOD (2004)
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1
S Hacein-Bey-Abina et al.
SCIENCE (2003)
Biallelic inactivation of BRCA2 in Fanconi anemia
NG Howlett et al.
SCIENCE (2002)
Impaired DNA damage-induced nuclear Rad51 foci formation uniquely characterizes Fanconi anemia group D1
BC Godthelp et al.
ONCOGENE (2002)
Attenuation of the formation of DNA-repair foci containing RAD51 in Fanconi anaemia
M Digweed et al.
CARCINOGENESIS (2002)
Reverse mosaicism in Fanconi anemia: natural gene therapy via molecular self-correction
M Gross et al.
CYTOGENETIC AND GENOME RESEARCH (2002)
The emerging genetic and molecular basis of Fanconi anaemia
H Joenje et al.
NATURE REVIEWS GENETICS (2001)
Somatic mosaicism in Fanconi anemia: Evidence of genotypic reversion in lymphohematopoietic stem cells
JJ Gregory et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin
A Bhattacharyya et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
